Psoriatic arthritis management update - Biotherapeutic options

Journal of Rheumatology

Volumn 36, Issue SUPPL. 83, 2009, Pages 65-68

  Saber, Tajvur P ^a   Veale, Douglas J ^a,b,c  

^a Dublin Academic Health Care   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Biotherapeutics; Management; Psoriatic arthritis; Spondyloarthopathy

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; BIOLOGICAL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

BIOLOGICAL THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; INFECTION; LOADING DRUG DOSE; LUPUS LIKE SYNDROME; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SPONDYLOARTHROPATHY; TREATMENT INDICATION; TREATMENT RESPONSE; DRUG ANTAGONISM; REVIEW;

ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; CLINICAL TRIALS AS TOPIC; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349909601     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090229     Document Type: Conference Paper

References (19)

1. Mease P. Psoriatic arthritis update. BullNYUHosp Jt 2006;64:25-31.
2. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: a systematic review. J Rheumatol 2008;35:1354-1358 (Pubitemid 352000783)
3. Maugars Y, Matthias C, Vilon P, et al. Corticosteroid injection of the sacroiliac joints in patients with seronegative spondyloarthropathy. Arthritis Rheum 1992;35:564-568
4. Maugars Y,Matthias C, Berthelot J, et al. Assessment of the efficacy of sacroiliac corticosteroid injection in spondyloarthropathy: a double-blind study. Br J Rheumatol 1996;35:767-770 (Pubitemid 126719537)
5. Gunaydin I, Pereira PL, Daikeles T, et al.MRI guided corticosteroid injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: A pilot study. J Rheumatol 2000;27:424-428 (Pubitemid 30095476)
6. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human TNF receptor (p75) Fc fusion protein. N Eng J Med 1997;337:141-148
7. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-TNF alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase 3 trial. Lancet 1999;354:1932-1939.
8. Sandborn WJ, Hanauer SB. Anti-tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999;5:119-133
9. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regime of 3 infusions of chimeric monoclonal antibody to TNF alpha (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59:428-433 (Pubitemid 30395599)
10. Kruithof E, Van den Bosch F, Baeten D, et al. Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-212 (Pubitemid 34177749)
11. Markham T, Mullan R, Golden-Mason L, et al. Resolution of endothelial activation and downregulation of the Tie2 receptor in psoriasis skin following infliximab therapy. J Am Acad Dermatol 2006;54:1003-1012 (Pubitemid 44729994)
12. Markham T, Mathews C, Rogers S, et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. Br J Dermatol 2006;155:1191-1196 (Pubitemid 44729994)
13. Baeten D, Kruithof E, Van den Bosch F, et al. Immunomodulatory effects of anti TNF-α therapy on synovium in spondyloarthropathy. Arthritis Rheum 2001;44:186-195
14. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomized trial. Lancet 2000;356:385-390 (Pubitemid 30487495)
15. Alonso Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumour necrosis factor alpha drugs in rheumatoid arthritis: systemic review and meta-analysis of efficacy and safety. BMC Musculoskel Disord 2008;9:52. (Pubitemid 351678129)
16. Marra CA. Valuing health states and preferences of patients. Ann Rheum Dis 2005;64 Suppl 3:36.
17. Guh D, Bansback N, Nosyk B, Melilli L, Anis A. Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 2005;64 Suppl 3:401.
18. Bansback N, Barkham N, Ara R, et al. The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis [abstract]. Arthritis Rheum 2004;50 Suppl:S509.
19. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104 (Pubitemid 34940777)